More Geron Corporation news Geron CorporationNASDAQ: GERN Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients Jun 2, 2023 · Issued by Geron Corporation On 6ix: 6ix.com/news/geron-announces-asco-presentation-reporting-durable-continuous-transfusionWatch Geron's latest callGeron (NASDAQ:GERN) Q3 2026 Earnings Call · Replay · Nov 4↗Primary endpoint of 8-week transfusion independence (TI) significantly higher with imetelstat vs. placebo (P Geron Corporation on 6ix Story so farGeron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3May 25, 2023Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3May 11, 2023Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS TrialApr 26, 2023 Earlier from GeronGeron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3May 25, 2023Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3May 11, 2023Geron Corporation Reports First Quarter 2023 Financial Results and Business HighlightsMay 11, 2023Geron to Announce First Quarter 2023 Financial Results on May 11, 2023May 4, 2023Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS TrialApr 26, 2023Later from GeronGeron to Host Virtual Investor Event on June 14, 2023Jun 6, 2023Geron to Participate in Goldman Sachs 44th Annual Global Healthcare ConferenceJun 7, 2023Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS PatientsJun 12, 2023Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDSJun 13, 2023Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor ImetelstatJun 20, 2023All Geron news releases↗Follow Geron into a list and get an email when it puts out news.Follow Geron